Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well brostallicin and cisplatin work in treating patients
with breast cancer that has spread to other parts of the body (metastatic) and does not have
estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor
receptor 2 (HER2) on its cells (triple-negative). Drugs used in chemotherapy, such as
brostallicin and cisplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from spreading.